The transaction is due to close before the current third quarter of 2022, following regulatory approvals. Albumedix will then become part of the Sartorius Bioprocess Solutions division. The UK company’s Nottingham site will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials.

Recombinant human albumin is a critical component for the biopharmaceuticals sector, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. Sartorius said the market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications.

Albumedix is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company, said René Fáber, member of the executive board for the Sartorius Bioprocess Solutions division.

Fáber said Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding its cell culture media business, enabling the company to strengthen its position as a relevant supplier of innovative chemically defined media and critical ancillary materials.

Jonas S. Møller, CEO of Albumedix, said he believes Sartorius will bring “tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform.”

Author: Dede Williams, Freelance Journalist